Open AccessInfluence of statin therapy on antiphospholipid antibodies and endothelial dysfunction in young patients with coronary artery disease and systemic lupus erythematosus
Author(s) -
Adam Mazurek,
Krzysztof Gryga,
Kamil Bugała,
Teresa Iwaniec,
Jacek Musiał,
Piotr Podolec,
Wojciech Płazak
Publication year - 2019
Publication title -
archives of medical science/archives of medical science (online)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 46
eISSN - 1896-9151
pISSN - 1734-1922
DOI - 10.5114/aoms.2019.90271
Subject(s) - medicine , coronary artery disease , lupus anticoagulant , statin , antiphospholipid syndrome , endothelial dysfunction , atorvastatin , gastroenterology , systemic lupus erythematosus , antibody , immunology , cardiology , thrombosis , disease
Antiphospholipid antibodies (aPL) affect atherogenesis and may cause thromboembolism in systemic lupus erythematosus (SLE) and coronary artery disease (CAD). Intensive treatment with statins may reduce inflammation and decrease the number of thrombotic events. That may explain the beneficial effect of statin therapy in SLE and CAD. This study was established to investigate the influence of statin treatment on aPL antibody levels and selected endothelial dysfunction markers in CAD and SLE patients.